These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1288 related items for PubMed ID: 19584683
1. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group. Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683 [Abstract] [Full Text] [Related]
2. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E, RAD A2420 Study Group. Transpl Int; 2010 Nov 15; 23(11):1084-93. PubMed ID: 20500493 [Abstract] [Full Text] [Related]
3. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. Tedesco-Silva H, Lorber MI, Foster CE, Sollinger HW, Mendez R, Carvalho DB, Shapiro R, Rajagopalan PR, Mayer H, Slade J, Kahan BD, FTY720A2202 clinical study group. Clin Transplant; 2009 Nov 15; 23(5):589-99. PubMed ID: 19719728 [Abstract] [Full Text] [Related]
4. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH. Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999 [Abstract] [Full Text] [Related]
5. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW. Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948 [Abstract] [Full Text] [Related]
6. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E. Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352 [Abstract] [Full Text] [Related]
7. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group. J Heart Lung Transplant; 2008 Feb 27; 27(2):197-202. PubMed ID: 18267227 [Abstract] [Full Text] [Related]
8. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients. Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M. Transplant Proc; 2005 Mar 27; 37(2):839-42. PubMed ID: 15848550 [Abstract] [Full Text] [Related]
9. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group. Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978 [Abstract] [Full Text] [Related]
10. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM, Everolimus Pediatric Study Group. Pediatr Transplant; 2008 Jun 27; 12(4):456-63. PubMed ID: 18466433 [Abstract] [Full Text] [Related]
11. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F. Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150 [Abstract] [Full Text] [Related]
12. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction. Patel SJ, Duhart BT, Krauss AG, Moore LW, Egidi MF, Amiri HS, Gaber LW, Gaber AO. Transplantation; 2008 Jul 27; 86(2):313-20. PubMed ID: 18645496 [Abstract] [Full Text] [Related]
13. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression. Iaria G, Pisani F, Iorio B, Lucchesi C, De Luca L, Ielpo B, D'Andria D, Tariciotti L, Tisone G. Transplant Proc; 2006 May 27; 38(4):1018-9. PubMed ID: 16757249 [Abstract] [Full Text] [Related]
14. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience. Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA. Transplant Proc; 2012 Jan 27; 44(1):154-60. PubMed ID: 22310603 [Abstract] [Full Text] [Related]
15. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C. Transplantation; 2009 Nov 27; 88(10):1194-202. PubMed ID: 19935373 [Abstract] [Full Text] [Related]
16. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L. Liver Transpl; 2006 Nov 27; 12(11):1640-8. PubMed ID: 16598777 [Abstract] [Full Text] [Related]
17. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Pascual J, del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernández AM, Brunet M. Transplantation; 2010 Apr 27; 89(8):994-1000. PubMed ID: 20335831 [Abstract] [Full Text] [Related]
18. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS. Transplantation; 2015 Jan 27; 99(1):180-6. PubMed ID: 24983307 [Abstract] [Full Text] [Related]
19. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups. Transpl Int; 2007 Jan 27; 20(1):27-36. PubMed ID: 17181650 [Abstract] [Full Text] [Related]
20. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Baboolal K. Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239 [Abstract] [Full Text] [Related] Page: [Next] [New Search]